title: Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry).
abstract: It yet has not been clarified whether there is a late catch-up phenomenon in target lesion revascularization (TLR) after sirolimus-eluting stent (SES) compared to bare metal stent (BMS) implantation. In 12,824 patients enrolled in the j-Cypher Registry, incidences of early (within first year) and late (1 year to 3 years) TLR were compared between 17,050 lesions treated with SESs and 1,259 lesions treated with BMSs. Incidences of TLR in SES-treated lesions were 5.7% at 1 year, 8.1% at 2 years, and 10.0% at 3 years, whereas those in BMS-treated lesions were 14.2%, 15.5%, and 15.5%, respectively (p <0.0001, log-rank test). Incidences of late TLR were significantly higher with SESs compared to BMSs (2.6% vs 1.4% at 2 years and 4.5% vs 1.4% at 3 years, p = 0.0007, log-rank test). A multivariable logistic regression model identified 7 independent risk factors for late TLR at 3 years after SES implantation: hemodialysis, low estimated glomerular filtration rate, ostial right coronary artery, lesion length >or=30 mm, 2 stents for bifurcation, American Heart Association/American College of Cardiology type B2/C, and vessel size <2.5 mm. Of these, 5 factors were common to those for early TLR. In conclusion, a late catch-up phenomenon was observed as indicated by the increasing incidence of late TLR after SES, but not after BMS, implantation. Risk factors for late TLR were generally common to those for early TLR.
authors.affiliation: Division of Cardiology, Tenri Hospital, Tenri, Japan. nakagawa@tenriyorozu-hp.or.jp
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Nakagawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kimura
authors.forename: Takeshi
authors.initials: T
authors.lastname: Morimoto
authors.forename: Masanori
authors.initials: M
authors.lastname: Nomura
authors.forename: Keijiro
authors.initials: K
authors.lastname: Saku
authors.forename: Seiichi
authors.initials: S
authors.lastname: Haruta
authors.forename: Toshiya
authors.initials: T
authors.lastname: Muramatsu
authors.forename: Masakiyo
authors.initials: M
authors.lastname: Nobuyoshi
authors.forename: Kazushige
authors.initials: K
authors.lastname: Kadota
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fujita
authors.forename: Ryozo
authors.initials: R
authors.lastname: Tatami
authors.forename: Nobuo
authors.initials: N
authors.lastname: Shiode
authors.forename: Hideo
authors.initials: H
authors.lastname: Nishikawa
authors.forename: Yoshisato
authors.initials: Y
authors.lastname: Shibata
authors.forename: Shunichi
authors.initials: S
authors.lastname: Miyazaki
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Murata
authors.forename: Takashi
authors.initials: T
authors.lastname: Honda
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kawasaki
authors.forename: Osamu
authors.initials: O
authors.lastname: Doi
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Hiasa
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Masunori
authors.initials: M
authors.lastname: Matsuzaki
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Mitsudo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016009:Chi-Square Distribution; D023903:Coronary Restenosis / Q000453:epidemiology / Q000517:prevention & control*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015994:Incidence; D016015:Logistic Models; D008297:Male; D012042:Registries; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus